Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194699 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 856
- Enrollment target
NCT02194699 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 856 participants.
The verdict
NCT02194699, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 856 participants
- Enrollment target
Study Summary
A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Interventions
- OTHER Placebo
- BIOLOGICAL Experimental: Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 856 participants |
| Start Date | 2014-10-30 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02194699
The ClinicalTrials.gov registry entry for NCT02194699 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 856 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02194699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02194699 about?
NCT02194699 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma". A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
What is the current status of trial NCT02194699?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 856 participants. The study started on 2014-10-30. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02194699?
The interventions under investigation include: Placebo (OTHER), Experimental: Tralokinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02194699?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.